RE:RE:RE:Zenith callHi GV.
Don should hold up under any questions even if not presripted! He is an $850,000/year paid executive that has been at this for 16 years and he is also involved in other businesses. One thing for sure, we all let Don off far too easy! This guy doesn't even present at the level of a first year business student and he presents science he does not understand. The term "snake oil" has been used to describe Don and I am beginning to believe it applies quite well!
That being said, we all know that the money flows into Zenith and RVX because of the science and not Don. As long as he steadies the ship I'm OK because if that changes things could get really mean and nasty.
We all know that unless one of the orphan trials or the zen3694 mCRPC trial hits a home run there will be no money to be made here for many years unless of course some BP finally gets interested, but at this stage I sense the traditional BP have analysed Zenith and RVX and have set it aside. Otherwise we'ed see a CVR deal coming through.
Regarding the 1500 compounds (and I will have to check the records) I thought that Zenith had 2400 and RVX had 1500 based on either the Jan 7th presentation or the Feb RVX update. Either I am wrong (and I could well be) or it's just another sloppy error on Don's behalf OR they actually shifted the portfollio mix.
Bottom line for me is obviously disappointment but I remain very excited by the science and it will carry on at the pace it takes to get things done.
I posted here because my thoughts would not be welcome on Agora where I am not allowed to mention compensation, or to be critical, etc. I'm looking forward to different perspectives from others.
Unless there a breakthrough on any one of the many possibilities such as FDA BoM approval we, as investors, have an extremely long journey ahead of us.
GLTA
Toinv